Charles River Laboratories and The Tri-Insitutional Therapeutics Discovery Institute Announce Strategic Partnership
September 22 2016 - 8:00AM
Business Wire
Partnership Intends to Accelerate
Translation of Discoveries into Novel Therapies for
Patients
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced that it has entered into a strategic partnership
agreement with The Tri-Institutional Therapeutics Discovery
Institute (Tri-I TDI), intended to accelerate the development of
therapeutics that arise from discoveries made in Tri-I TDI’s
academic labs.
Tri-I TDI is a cooperative endeavor of Memorial Sloan Kettering
Cancer Center, The Rockefeller University, and Weill Cornell
Medicine, with a focus on the early stages of compound and biologic
agent development, as well as “proof of concept” studies that
determine which drug candidates can successfully alter the course
of a disease.
“This partnership reinforces Charles River’s continued
commitment to expedite the early-stage development of innovative
treatments and therapies for patients,” said Dr. Emily Hickey,
Corporate Senior Vice President, Global Discovery Services, Charles
River. “Our new partnership will leverage Charles River’s drug
discovery and safety assessment expertise with both Tri-I TDI’s
research strengths and the cutting-edge work of their member
institutions’ scientific leaders.”
Through this partnership, Charles River will provide Tri-I TDI
with discovery and safety assessment services to support a range of
projects that are at the frontier of science. The collaboration
will enhance Tri-I TDI’s efforts to more effectively develop
therapeutics for unmet medical needs.
“Our partnership with Charles River opens up a new pathway to
innovation for Tri-I TDI,” said Michael A. Foley, Chief Executive
Officer, Tri-I TDI. “Its decades of experience in drug discovery
and safety assessment, combined with a robust portfolio of
services, will provide us with additional capabilities to rapidly
advance our projects.”
About The Tri-Institutional Therapeutics Discovery
Institute
The Tri-Institutional Therapeutics Discovery Institute (Tri-I
TDI). Tri-I TDI is a partnership of three world-renowned scientific
and medical institutions — Memorial Sloan Kettering Cancer Center,
The Rockefeller University and Weill Cornell Medicine. A novel
partnership of academic institutions, the Tri-I TDI links
researchers in basic and clinical science with experts in drug
discovery from the biotech and pharmaceutical industries, with the
goal of more efficiently translating discoveries into therapies for
disease. Launched in 2013 in New York City the Tri-I TDI focuses on
the early stages of developing compounds and biologic agents, and
conducts “proof of concept” studies needed to demonstrate that drug
candidates can successfully alter the course of a disease. To learn
more, visit www.tritdi.org.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160922005165/en/
Charles River Laboratories International, Inc.Investor
Contact:Susan E. Hardy, 781-222-6190Corporate Vice President,
Investor Relationssusan.hardy@crl.comorMedia Contact:Amy
Cianciaruso, 781-222-6168Corporate Vice President, Public
Relationsamy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Apr 2023 to Apr 2024